Key Facts GPs Should Know About GLP-1 Analogs
Family Medicine Initiative
APRIL 9, 2024
4 Chronic Kidney Disease The FLOW trial randomized 3,534 patients with chronic kidney disease and type 2 diabetes and started treating them with s.c. mg or placebo in 2019. Both the FDA and EMA recommend that doctors monitor patients with diabetic retinopathy who are undergoing semaglutide treatment closely. semaglutide 1.0
Let's personalize your content